ampelopsin has been researched along with Liver Steatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, L; Yan, X; Zhang, H | 1 |
| Chen, Z; Han, T; Jin, J; Wang, J; Xie, C; Xu, X; Zhan, W; Zhang, C | 1 |
2 other study(ies) available for ampelopsin and Liver Steatosis
| Article | Year |
|---|---|
Protective effect of dihydromyricetin revents fatty liver through nuclear factor‑κB/p53/B‑cell lymphoma 2‑associated X protein signaling pathways in a rat model.
Topics: Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; bcl-2-Associated X Protein; Disease Models, Animal; Fatty Liver; Flavonols; Gene Expression Regulation; Humans; Inflammation; Liver; NF-kappa B; Oxidative Stress; Rats; Signal Transduction; Superoxide Dismutase; Tumor Suppressor Protein p53 | 2019 |
Dihydromyricetin ameliorates oleic acid-induced lipid accumulation in L02 and HepG2 cells by inhibiting lipogenesis and oxidative stress.
Topics: Fatty Liver; Flavonols; Hep G2 Cells; Humans; Lipid Metabolism; Lipogenesis; Oleic Acid; Oxidative Stress | 2016 |